Literature DB >> 3588249

Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

R Van Dalen, T B Vree, I M Baars.   

Abstract

A pharmacokinetic study after a single dose of ceftriaxone, cefoxitin, cefuroxime and ceftazidime was performed to investigate the influence of protein binding and severity of disease on the renal elimination. In intensive-care patients drug-protein binding was substantially less compared to that in volunteers and patients with less complicated diseases. This did not result in increased elimination but, due to increased apparent volumes of distribution, prolonged half-life times were observed. Consequently, in patients with complicated disease states a dosage regimen should be based on pharmacokinetic studies performed in a similar patient group.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3588249     DOI: 10.1007/bf01960743

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  19 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 2.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

3.  Protein binding and drug clearance.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

4.  Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.

Authors:  B E Scully; K P Fu; H C Neu
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

5.  Single-dose ceftriaxone kinetics in functionally anephric patients.

Authors:  K Stoeckel; P J McNamara; G Hoppe-Seyler; A Blumberg; E Keller
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

6.  Clinical pharmacology: plasma protein binding of drugs.

Authors:  W E Lindup; M C Orme
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-17

7.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

Review 9.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

10.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

View more
  9 in total

Review 1.  Pharmacokinetics of antimicrobial agents in organ function impairment. A review.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

Review 2.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.

Authors:  J Lipman; S C Wallis; C Rickard
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 5.  The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Authors:  Marta Ulldemolins; Jason A Roberts; Jordi Rello; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

6.  Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Authors:  Rachel F Eyler; A Mary Vilay; Ahmed M Nader; Michael Heung; Melissa Pleva; Kevin M Sowinski; Daryl D DePestel; Fritz Sörgel; Martina Kinzig; Bruce A Mueller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

7.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis.

Authors:  Christer Rimmler; Christian Lanckohr; Ceren Akamp; Dagmar Horn; Manfred Fobker; Karsten Wiebe; Bassam Redwan; Bjoern Ellger; Robin Koeck; Georg Hempel
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 4.335

9.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.